Abbott has announced the availability of Navitor, its next-generation transcatheter aortic valve implantation (TAVI) system, in India for people with severe aortic stenosis who are at high or extreme surgical risk.
The company is advancing TAVI (also known as "TAVR" or transcatheter aortic valve replacement) therapies with the Navitor valve, which features a unique design that prevents blood from leaking around the valve. The Navitor TAVI system is the most recent addition to the company's extensive structural heart transcatheter portfolio, which provides physicians and patients with less invasive heart disease treatment options.
The most prevalent and potentially fatal heart valve condition is aortic stenosis. It limits blood flow from the heart to the rest of the body through the aortic heart valve, which can cause heart failure and, in some circumstances, sudden cardiac death.
One in 40 Indians aged 75 and older has severe, symptomatic aortic stenosis, even though many don't exhibit any symptoms.
Given their advanced age, fragility, or many diseases or ailments, open heart surgery is a high-risk procedure for these patients.
TAVI offers individuals with this crippling ailment a less intrusive option to surgical aortic valve replacement that can lessen symptoms and enhance the quality of life.
"This TAVI device provides a secure and efficient therapeutic alternative for aortic stenosis patients in India who cannot undergo surgery. "The available size ranges enable patient-specific sizing and ideal valve performance", said Dr. Ashok Seth, the chairman of the Fortis Medical Council and the Fortis Escorts Heart Institute in New Delhi.
"While transcatheter valve replacement has long been the standard of care for elderly patients with narrowing of the aortic valve, this device helps to address challenges we occasionally find in current TAVI systems when we encounter challenging patient anatomies which may lead to potential problems and difficulties," says the manufacturer of the device.
